FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2909224113> ?p ?o ?g. }

• W2909224113 endingPage "588" @default.
• W2909224113 startingPage "580" @default.
• W2909224113 abstract "PURPOSE Salvage options for patients who relapse after allogeneic stem-cell transplantation (allo-SCT) for acute myeloid leukemia (AML) and myelodysplasia (MDS) remain limited, and novel treatment strategies are required. Both lenalidomide (LEN) and azacitidine (AZA) possess significant antitumor activity effect in AML. Administration of LEN post-transplantation is associated with excessive rates of graft-versus-host disease (GVHD), but AZA has been shown to ameliorate GVHD in murine transplantation models. We therefore examined the tolerability and activity of combined LEN/AZA administration in post-transplantation relapse. PATIENTS AND METHODS Twenty-nine patients who had relapsed after allo-SCT for AML (n = 24) or MDS (n = 5) were treated with sequential AZA (75 mg/m 2 for 7 days) followed by escalating doses of LEN on days 10 to 30. Dose allocation and maximum tolerated dose (MTD) estimation were guided by a modified Bayesian continuous reassessment method (CRM). RESULTS Sequential AZA and LEN therapy was well tolerated. The MTD of post-transplantation LEN, in combination with AZA, was determined as 25 mg daily. Three patients developed grade 2 to 4 GVHD. There was no GVHD-related mortality. Seven of 15 (47%) patients achieved a major clinical response after LEN/AZA therapy. CD8+ T cells demonstrated impaired interferon-γ/tumor necrosis factor–α production at relapse, which was not reversed during LEN/AZA administration. CONCLUSION We conclude LEN can be administered safely post-allograft in conjunction with AZA, and this combination demonstrates clinical activity in relapsed AML/MDS without reversing biologic features of T-cell exhaustion. The use of a CRM model delivered improved efficiency in MTD assessment and provided additional flexibility. Combined LEN/AZA therapy represents a novel and active salvage therapy in patients who had relapsed post-allograft." @default.
• W2909224113 created "2019-01-25" @default.
• W2909224113 creator A5016790466 @default.
• W2909224113 creator A5019472985 @default.
• W2909224113 creator A5023774667 @default.
• W2909224113 creator A5028677250 @default.
• W2909224113 creator A5035067892 @default.
• W2909224113 creator A5045070181 @default.
• W2909224113 creator A5046497654 @default.
• W2909224113 creator A5047320329 @default.
• W2909224113 creator A5052506270 @default.
• W2909224113 creator A5060426399 @default.
• W2909224113 creator A5070847211 @default.
• W2909224113 creator A5071939949 @default.
• W2909224113 creator A5076984999 @default.
• W2909224113 creator A5081233146 @default.
• W2909224113 date "2019-03-01" @default.
• W2909224113 modified "2023-09-27" @default.
• W2909224113 title "Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia" @default.
• W2909224113 cites W1415829101 @default.
• W2909224113 cites W1544829530 @default.
• W2909224113 cites W1600365609 @default.
• W2909224113 cites W1763981524 @default.
• W2909224113 cites W1965832312 @default.
• W2909224113 cites W1973765711 @default.
• W2909224113 cites W1996418291 @default.
• W2909224113 cites W2017173402 @default.
• W2909224113 cites W2059465100 @default.
• W2909224113 cites W2074326274 @default.
• W2909224113 cites W2076108528 @default.
• W2909224113 cites W2087607698 @default.
• W2909224113 cites W2090352304 @default.
• W2909224113 cites W2099261151 @default.
• W2909224113 cites W2109948637 @default.
• W2909224113 cites W2133384656 @default.
• W2909224113 cites W2137062141 @default.
• W2909224113 cites W2149344761 @default.
• W2909224113 cites W2158740848 @default.
• W2909224113 cites W2159507916 @default.
• W2909224113 cites W2162300921 @default.
• W2909224113 cites W2239788766 @default.
• W2909224113 cites W2340869536 @default.
• W2909224113 cites W2341077074 @default.
• W2909224113 cites W2411964580 @default.
• W2909224113 cites W2483974275 @default.
• W2909224113 cites W2623089849 @default.
• W2909224113 cites W2738408027 @default.
• W2909224113 cites W2773723254 @default.
• W2909224113 cites W4376595466 @default.
• W2909224113 doi "https://doi.org/10.1200/jco.18.00889" @default.
• W2909224113 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6494237" @default.
• W2909224113 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30653424" @default.
• W2909224113 hasPublicationYear "2019" @default.
• W2909224113 type Work @default.
• W2909224113 sameAs 2909224113 @default.
• W2909224113 citedByCount "47" @default.
• W2909224113 countsByYear W29092241132019 @default.
• W2909224113 countsByYear W29092241132020 @default.
• W2909224113 countsByYear W29092241132021 @default.
• W2909224113 countsByYear W29092241132022 @default.
• W2909224113 countsByYear W29092241132023 @default.
• W2909224113 crossrefType "journal-article" @default.
• W2909224113 hasAuthorship W2909224113A5016790466 @default.
• W2909224113 hasAuthorship W2909224113A5019472985 @default.
• W2909224113 hasAuthorship W2909224113A5023774667 @default.
• W2909224113 hasAuthorship W2909224113A5028677250 @default.
• W2909224113 hasAuthorship W2909224113A5035067892 @default.
• W2909224113 hasAuthorship W2909224113A5045070181 @default.
• W2909224113 hasAuthorship W2909224113A5046497654 @default.
• W2909224113 hasAuthorship W2909224113A5047320329 @default.
• W2909224113 hasAuthorship W2909224113A5052506270 @default.
• W2909224113 hasAuthorship W2909224113A5060426399 @default.
• W2909224113 hasAuthorship W2909224113A5070847211 @default.
• W2909224113 hasAuthorship W2909224113A5071939949 @default.
• W2909224113 hasAuthorship W2909224113A5076984999 @default.
• W2909224113 hasAuthorship W2909224113A5081233146 @default.
• W2909224113 hasBestOaLocation W29092241131 @default.
• W2909224113 hasConcept C104317684 @default.
• W2909224113 hasConcept C126322002 @default.
• W2909224113 hasConcept C143998085 @default.
• W2909224113 hasConcept C150194340 @default.
• W2909224113 hasConcept C185592680 @default.
• W2909224113 hasConcept C190727270 @default.
• W2909224113 hasConcept C197934379 @default.
• W2909224113 hasConcept C2776063141 @default.
• W2909224113 hasConcept C2776239401 @default.
• W2909224113 hasConcept C2776364478 @default.
• W2909224113 hasConcept C2776694085 @default.
• W2909224113 hasConcept C2778375690 @default.
• W2909224113 hasConcept C2778729363 @default.
• W2909224113 hasConcept C2780775027 @default.
• W2909224113 hasConcept C2911091166 @default.
• W2909224113 hasConcept C55493867 @default.
• W2909224113 hasConcept C71924100 @default.
• W2909224113 hasConcept C90924648 @default.
• W2909224113 hasConceptScore W2909224113C104317684 @default.
• W2909224113 hasConceptScore W2909224113C126322002 @default.
• W2909224113 hasConceptScore W2909224113C143998085 @default.

• next